BioCentury | May 1, 2020
Distillery Therapeutics

The lipids LXA4 and RvD1 as treatment for E. coli pneumonia

...FPRL1, could treat E. coli pneumonia by promoting antibacterial functions in neutrophils. The release of neutrophil elastase...
...granulocytes cultured with CpG, LXA4 and RvD1 saw restored phagocytosis, increased phagocytosis-induced apoptosis and reduced neutrophil elastase...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

Susan Desmond-Hellmann joined VC firm GV as an adviser. She recently joined the board of Pfizer Inc. (NYSE:PFE) after stepping down as CEO of the Bill & Melinda Gates Foundation in December. Previously, she spent...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

...Low and high dose INS1007 vs. placebo also reduced sputum concentrations from baseline of activated ELANE...
...at an upcoming medical meeting. Targets DPP-1 (CTSC) - Dipeptidyl peptidase-1 ELANE (NE; HLE) - Neutrophil elastase...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BioCentury | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal. The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain...
BioCentury | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

...Inc. (Irvine, Calif.), cancer detection play Hawkeye Bio (Westlake Village, Calif.) and surgical software company NE...
...& Johnson Merck & Co. Inc. Novavax Inc. Sanofi Thrombopoietin (TPO) receptor (CD110) (Mpl) Tyrosine kinase 2 (TYK2) Thrombocytopenia Meningitis Hawkeye Bio JLABS @ Shanghai MenQuadfi NE...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BioCentury | Dec 14, 2018
Company News

Mereo, OncoMed announce merger

...mAb against sclerostin, in Phase IIb testing for osteogenesis imperfecta; and MPH-966, a neutrophil elastase (ELANE; NE...
...Redwood City, Calif. Business: Musculoskeletal, Endocrine/Metabolic, Cancer Mark Zipkin BPS804, BPS-804 MPH-966, alvelestat (AZD9668) Mereo BioPharma Group plc OncoMed Pharmaceuticals Inc. Neutrophil elastase (ELANE) (NE) (HLE) Sclerostin...
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
BioCentury | Sep 28, 2018
Preclinical News

Two strategies block immune-mediated metastases in mice

...two models of dormant breast cancer, knockout or pharmacological inhibition of NET-associated proteases neutrophil elastase (ELANE; NE...
...and NET formation. The researchers found that sequential cleaving of an isoform of laminin by ELANE...
...chemotherapeutic with known immunostimulatory effects. Mark Zipkin Cold Spring Harbor Laboratory National Tumor Institute University of Milan Matrix metalloproteinase 9 (MMP9) Neutrophil elastase (ELANE) (NE) (HLE) Neutrophil...
Items per page:
1 - 10 of 2433